Until recently, the treatment of higher risk myelodysplastic syndrome was based on [1]
Intensive chemotherapy using anthracycline–AraC combinations, leading to a lower …

BACKGROUND AND OBJECTIVES: Intensive chemotherapy followed by autologous
hematopoietic stem cell transplantation (HSCT) is a curative treatment option for patients …

Decitabine and CHG regimen (low-dose cytarabine and homoharringtonine with G-CSF)
have been used for treating higher risk myelodysplastic syndrome (MDS). In this study, we …

The optimal treatment for use as a bridge to allogeneic hematopoietic stem cell
transplantation at the decision for transplantation has not been established in patients with …

Within the past years, reduced or modified doses of chemotherapy or radiotherapy have
been widely studied for conditioning before allogeneic hematopoietic cell transplantation in …

Despite new developments in innovative and potentially targeted drugs like hypomethylating
agents (HMA), allogeneic hematopoietic stem cell transplantation (HCT) is still the only …

Two main forms of therapy‐related myelodysplastic syndrome and acute myeloid leukemia (t‐
MDS/AML) have been recognized. The most frequent type, occurring after treatment with …

Allogeneic hematopoietic stem cell transplantation remains the only curative option for
myelodysplastic syndrome, but patients with this disease are often older and frail, and …

Although high-dose chemotherapy may cure a small subset of patients with myelodysplastic
syndrome (MDS), allogeneic hematopoietic cell transplantation (HCT) is the only currently …

Allogeneic stem cell transplantation (SCT) is the treatment of choice for the majority of young
patients with myelodysplasia (MDS) who have a histocompatible donor (sibling or unrelated …